Dyadic International (DYAI) Total Liabilities (2017 - 2026)
Dyadic International's (DYAI) quarterly Total Liabilities came in at $8.2 million in Q1 2026, up 17.87% year-over-year from $7.0 million in Q1 2025, and down 5.69% quarter-over-quarter from $8.7 million in Q4 2025.
Analysis
Dyadic International (DYAI) Total Liabilities (2017 - 2026) Analysis & Trends
Dyadic International has disclosed Total Liabilities across 10 years of filings, most recently posting $8.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 17.87% year-over-year to $8.2 million; the TTM figure through Mar 2026 stood at $8.2 million (up 17.87% YoY), while the FY2025 annual figure was $8.7 million, up 16.8% from the prior year.
- Total Liabilities came in at $8.2 million for Q1 2026 at Dyadic International, down from $8.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $2.1 billion in Q1 2022 to a low of $1.6 million in Q3 2023.
- Average Total Liabilities over 5 years is $130.8 million, with a median of $7.4 million recorded in 2024.
- Year-over-year, Total Liabilities surged 82225.6% in 2022 and tumbled 99.91% in 2023.
- Over 5 years, Total Liabilities stood at $2.6 million in 2022, then retreated by 10.84% to $2.3 million in 2023, then jumped by 218.71% to $7.5 million in 2024, then grew by 16.8% to $8.7 million in 2025, then slipped by 5.69% to $8.2 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $9.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Dyadic International | 17.78 Mn | 9.82 Mn | - | 8.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 8.22 Mn |
| Dec 31, 2025 | 8.71 Mn |
| Sep 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 8.67 Mn |
| Mar 31, 2025 | 6.97 Mn |
| Dec 31, 2024 | 7.46 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 7.46 Mn |
| Mar 31, 2024 | 8.17 Mn |
| Dec 31, 2023 | 2.34 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 2.09 Mn |
| Mar 31, 2023 | 2.01 Mn |
| Dec 31, 2022 | 2.63 Mn |
| Sep 30, 2022 | 2.61 Mn |
| Jun 30, 2022 | 3.66 Mn |
| Mar 31, 2022 | 2.14 Bn |
| Dec 31, 2021 | 2.91 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 3.29 Mn |